SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in JapanArticle Published on 2022-10-012022-11-15 Journal: Clinical and experimental nephrology [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome anti-SARS-CoV-2 spike protein antibody Antibody titer Antibody titers BNT162b2 calculated clinics conducted contributed controls coronavirus death dose FIVE HD group healthy control Hemodialysis immune response Japan linear log log-transformed Lower mixed-effects model mRNA vaccination mRNA vaccine Patient patients Pfizer-BioNTech Prevent Protein reduced remained Retrospective study S1 IgG SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 spike protein second dose second vaccination shown significantly significantly lower vaccination Vaccine vaccine. were measured [DOI] 10.1007/s10157-022-02243-8 PMC 바로가기
Flare-up of generalized pustular psoriasis following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: Two cases without mutations of IL36RN and CARD14 genesArticle Published on 2022-10-012022-11-16 Journal: The Journal of dermatology [Category] 변종, [키워드] BNT162b2 mRNA CARD14 COVID-19 IL36RN Mutation Pfizer-BioNTech [DOI] 10.1111/1346-8138.16442 PMC 바로가기
Similar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the UAEArticle Published on 2022-09-172022-11-16 Journal: Journal of Travel Medicine [Category] Fulltext, MERS, 변종, [키워드] arising B.1.617.2 BBIBP-CorV BNT162b2 booster COVID-19 Delta demonstrated Effectiveness effort Hospitalization Inactivated vaccine mRNA vaccine outbreak Pfizer-BioNTech promote SARS-CoV-2 severe COVID-19 disease Sinopharm Vaccine vaccine effectiveness. Vaccine hesitancy variant variants of concern [DOI] 10.1093/jtm/taac036 PMC 바로가기
Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and AdultsArticle Published on 2022-09-142022-11-15 Journal: Journal of Virology [Category] SARS, 변종, 진단, [키워드] Adolescent adolescents adolescents and adult adolescents and adults Adults age antibody Antibody binding antibody binding titers approved Beta binding binding antibody BNT162b2 BNT162b2 vaccine booster booster dose booster vaccination breadth changes in children circulating clinical trial Cohort Coverage COVID-19 Delta demonstrated dose drug Effectiveness Efficacy evaluate FDA food Gamma highlight Hospitalization humoral immune response lack less Loss magnitude mounted mRNA vaccine neutralization Neutralizing antibody response omicron Omicron (B.1.1.529) pandemic pediatric Pfizer Pfizer-BioNTech Pfizer-BioNTech (BNT162b2) plasma populations PROTECT reduction reported Research response responses against robust SARS-CoV-2 seasonal beta coronavirus the antibody response the SARS-CoV-2 the vaccine vaccination Vaccine vaccine-induced antibody response Vaccine-induced immunity variant variant of concerns (VOCs) variants viral variant Virus neutralization virus neutralization. virus spike protein VoC VOCs while wild-type SARS-CoV-2 [DOI] 10.1128/jvi.00582-22 PMC 바로가기
Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 VaccineArticle Published on 2022-09-132022-11-15 Journal: Viruses [Category] SARS, 변종, 진단, [키워드] B.1.1.529 BNT162b2 collected COVID-19 dose evade Immunity Improved Lineage Mutation neutralisation assay neutralise neutralising Neutralising Antibodies neutralising antibody titre omicron Pfizer-BioNTech Pfizer-BioNTech BNT162b2 raising reduced SARS-CoV-2 sera the receptor-binding domain the SARS-CoV-2 the spike protein Vaccine vaccine. variant virus VoC World Health Organization [DOI] 10.3390/v14092023 PMC 바로가기
Humoral response to different SARS-CoV-2 vaccines in orthotopic liver transplant recipientsArticle Published on 2022-09-092022-11-15 Journal: Vaccine [Category] SARS, 진단, [키워드] Abbott Diagnostics Ad5-nCoV Analysis analyzed applied blood sample BNT162b2 BNT162b2 vaccine ChAdOx1 China Comorbidity Complete Control controls CoronaVac COVID-19 COVID-19 vaccine DiaSorin Efficacy evaluate Gam-COVID-Vac healthy healthy controls humoral Humoral response IgG immunosuppressants Italy life liver median Mexico mRNA-1273 multivariable model Oxford-AstraZeneca Pandemia participant Patient patients Pfizer-BioNTech platform positive Prednisone recipient recipients reduced SARS-CoV-2 vaccine Serologic response serological response Sinovac USA vaccination Vaccine vaccine doses Vaccines. women [DOI] 10.1016/j.vaccine.2022.08.027 PMC 바로가기
COVID-19 vaccination in people with multiple sclerosis, real-life experienceResearch article Published on 2022-09-012022-10-05 Journal: Clinical neurology and neurosurgery [Category] COVID19(2023년), SARS, 임상, [키워드] acute respiratory syndrome Adverse adverse events age approved association BNT162b2 BNT162b2 vaccine ChAdOx1 nCoV-19 Clinical data Cohort common adverse event Complete Complication coronavirus Coronavirus disease 2019 COVID-19 COVID-19 infection COVID-19 vaccination COVID-19 vaccine demographic disease dose event fatigue females Fever first dose General population increased risk Infection injection investigated Kuwait mRNA multiple sclerosis National objective Occurrence Pain Patient Pfizer-BioNTech questionnaire reduce Registered reported resolved Result risk Safe SARS-CoV-2 subjects Symptom Symptoms the vaccine Therapies therapy treated vaccination Vaccine virus were recorded WhatsApp worsening [DOI] 10.1016/j.clineuro.2022.107374 [Article Type] Research article
Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021Observational Study Published on 2022-09-012022-10-04 Journal: BMC Infectious Diseases [Category] SARS, 변종, 임상, [키워드] 95% CI age breakthrough infections caused CDC circulating COVID-19 COVID-19 vaccine COVID-19 vaccines effective Effectiveness evaluated Evaluating FIVE genomic higher risk immunization incidence individual infected with SARS-CoV-2 Infection Moderna National Observational data Pfizer-BioNTech Poisson regression models Prevent preventing infection proportion recipient recipients reported risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant Sex Surveillance vaccination Vaccine vaccine breakthrough infection Vaccine breakthrough infections. variants of concern virus with COVID-19 [DOI] 10.1186/s12879-022-07702-x PMC 바로가기 [Article Type] Observational Study
COVID-19 vaccine-related Guillain-Barré syndrome in the Liguria region of Italy: A multicenter case seriesShort communication Published on 2022-09-012022-10-05 Journal: Journal of the neurological sciences [Category] 변종, 유전자 메커니즘, [키워드] adverse event Affect age AstraZeneca Bilateral case sery characterized clinical clinical feature cohort of patient collected COVID-19 COVID-19 vaccination COVID-19 vaccines cranial dose feature first vaccination fluctuations Guillain-barrè syndrome hospital Inflammatory Italy Liguria Mild symptom Moderna multicenter negatively affected occur Oxford-AstraZeneca Patient patients Peripheral nervous system Pfizer-BioNTech post-COVID-19 vaccination predominant Prognosis Region Result SARS-CoV-2 second dose syndrome Treatment vaccination vaccine dose variant [DOI] 10.1016/j.jns.2022.120330 [Article Type] Short communication
Covid-19, an unfinished storyMini review Published on 2022-09-012022-10-05 Journal: La Presse Médicale [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] activities acute respiratory distress age amplitude bat coronavirus Beta Betacoronavirus caused China Cluster Comorbidities compulsory vaccination condition confirmed case coronavirus COVID-19 Critical cross deaths degree Delta detect development drug effective Efficacy epidemic waves epidemiological surveillance evade Face mask FIVE form Gamma Genome genomic Health highly pathogenic homogeneity Host Human immune response Immunity incidence rate include Inflammatory Innovation intensive care Measures Messenger RNA mild infection Moderna mRNA vaccine multiorgan failure nucleotides occupancy rate omicron Oxygen therapy pandemic Patient Pfizer-BioNTech Pneumonia preventing the transmission progressed Protective replaced RNA SARS-CoV-2 SARS-CoV-2 vaccine Sequencing severity syndrome the WHO thromboembolic complications Vaccine Vaccines variant variants variants of concern viral invasion VoC WHO World Health Organization [DOI] 10.1016/j.lpm.2022.104131 [Article Type] Mini review